Literature DB >> 6133361

Multiple endocrine adenopathy.

B M Greene, E S Golladay, D L Mollitt.   

Abstract

Since the original descriptions of the MEA syndrome, wide interest has been evinced for these familial endocrine disorders. Initially, screening investigations with the advent of the automated blood chemical analyses, and thus, the enhanced ease of detection of serum calcium levels have been followed by a flurry of diagnostic and therapeutic advances. Formal recognition of three MEA types, with their characteristics, has occurred over the last 20 years. Certainly in the future, other variants will be recognized and pose new problems. MEA poses fundamental questions of the embryologic origin and derivation of endocrine glands as well as issues of chromosomal operations of specific gene loci which have not yet been fully investigated.

Entities:  

Mesh:

Year:  1983        PMID: 6133361

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

1.  Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1.

Authors:  D Murphy; A Bishop; G Rindi; M N Murphy; G W Stamp; J Hanson; J M Polak; B Hogan
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

2.  The use of intraoperative sonography in endocrine tumors of the pancreas.

Authors:  H J Klotter; K Rückert; F Kümmerle; M Rothmund
Journal:  World J Surg       Date:  1987-10       Impact factor: 3.352

3.  Zollinger-Ellison syndrome, duodenal carcinoid (gastrinoma), and hyperthyroidism.

Authors:  R Theile; D Scharplatz; B Stamm; U P Veraguth
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Androgen producing adrenal adenoma. Report on a case associated with hyperparathyroidism.

Authors:  P J Guillausseau; C Boitard; Y Le Charpentier; L Cedard; K Nahoul; C Blacker; E Kaloustian; F Courtalhac-Kaloustian; C Dubost; J Lubetzki
Journal:  J Endocrinol Invest       Date:  1987-12       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.